Position in LLY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,919,088
+$447,456 QoQ
Shares Held
1,600
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
1.13%
of 13F equity value
Holder Rank
#2,534
of 4,605 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Pingora Partners LLC holds $9,651,164 across 10 Drug Manufacturers - General names. LLY ranks #3 (19.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
89,510 | $2,155,400 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
33,855 | $1,950,725 | |
| 3 | LLY |
ELI LILLY & Co
This page
|
1,600 | $1,919,088 | |
| 4 | MRK |
Merck & Co., Inc.
|
12,879 | $1,654,951 | |
| 5 | JNJ |
Johnson & Johnson
|
4,979 | $1,264,516 | |
| 6 | ABBV |
AbbVie Inc.
|
1,705 | $429,046 | |
| 7 | NVO |
Novo Nordisk A S
|
2,200 | $105,468 | |
| 8 | AMGN |
Amgen Inc
|
235 | $85,098 |
All Filings in LLY
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,919,088 | 1,600 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,471,632 | 1,600 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,826,956 | 1,700 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,297,100 | 1,700 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,247,248 | 1,600 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,569,229 | 1,900 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,466,800 | 1,900 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $1,683,286 | 1,900 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $1,720,222 | 1,900 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $1,478,124 | 1,900 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $1,107,548 | 1,900 | Shares | Sole | 2024-02-12 | |
| No filing history on record for this holder in this stock. | ||||||